Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Daniel S. Lefler, Steven Manobianco, Babar Bashir
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 13

Showing 13 citing articles:

CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis
Dariusz Szukiewicz
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4679-4679
Open Access | Times Cited: 15
A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats
Lorea Iturri, Emmanuel Jouglar, Cristèle Gilbert, et al.
Clinical and Translational Radiation Oncology (2025) Vol. 51, pp. 100911-100911
Closed Access | Times Cited: 1
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Lorena Ostios-García, Daniel Martínez-Pérez, Beatriz Castelo, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1561-1571
Open Access | Times Cited: 4
Classification of lung adenocarcinoma based on senescence-related genes identifies a cluster with immunotherapy resistance and poor prognosis
Xinrui Gao, Xiang Shen, Shasha Huang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota
Ali Rahimi, Zeinab Baghernejadan, Ali Hazrati, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 186, pp. 118014-118014
Closed Access
Trained innate immunity attenuates macrophage efferocytosis of cancer cells
Alexandros Chatzis, Jakub Lukaszonek, Dimitris Lagos, et al.
(2025)
Open Access
Trained innate immunity attenuates macrophage efferocytosis of cancer cells
Alexandros Chatzis, Jakub Lukaszonek, Dimitris Lagos, et al.
(2025)
Open Access
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy
Makoto Tahara, Wan‐Teck Lim, Bhumsuk Keam, et al.
Cancer Treatment Reviews (2025), pp. 102938-102938
Closed Access
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges
Alessandro Rizzo, Oronzo Brunetti, Giovanni Brandi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11091-11091
Open Access | Times Cited: 2
Drivers of Spatial Immune Heterogeneity in a Mouse Tumor Model after Immunotherapy
Michal Šmahel, Shweta Dilip Johari, Jana Šmahelová, et al.
(2024)
Closed Access
Revealing the mechanism of natural product-induced immunogenic cell death: opening a new chapter in tumor immunotherapy
Yukun Chen, Zhenzhi Wang, Chi Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Adoptive T cell therapies for solid tumors: T(I)ME is of the essence
Nour Amwas, Chu-Hsuan Chiu, Diana Gumber, et al.
EBioMedicine (2024) Vol. 109, pp. 105449-105449
Closed Access
Trained innate immunity attenuates macrophage efferocytosis of cancer cells
Alexandros Chatzis, Jakub Lukaszonek, Dimitris Lagos, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Spatial immune heterogeneity in a mouse tumor model after immunotherapy
Michal Šmahel, Shweta Dilip Johari, Jana Šmahelová, et al.
Cancer Science (2024)
Open Access
Page 1

Scroll to top